Management of inflammatory bowel disease with vitamin D: Beyond bone health

Journal of Crohn's and Colitis

Volumn 6, Issue 4, 2012, Pages 397-404

  Narula, Neeraj ^a   Marshall, John K ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Colon cancer; Crohn's disease; Inflammatory bowel disease; Osteoporosis; Ulcerative colitis; Vitamin D

Indexed keywords

7 DEHYDROCHOLESTEROL; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCIUM; CASPASE RECRUITMENT DOMAIN PROTEIN 15; COLECALCIFEROL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ERGOCALCIFEROL; GAMMA INTERFERON; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D; VITAMIN D RECEPTOR;

ANXIETY DISORDER; CANCER RISK; CD4+ T LYMPHOCYTE; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG SAFETY; ENTERITIS; FIBROMYALGIA; HIP FRACTURE; HUMAN; HYPERCALCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY CALCIFICATION; KIDNEY INJURY; MULTIPLE SCLEROSIS; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REGULATORY T LYMPHOCYTE; REVIEW; SEASONAL AFFECTIVE DISORDER; SUN EXPOSURE; TH1 CELL; ULCERATIVE COLITIS; ULTRAVIOLET B RADIATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

AUTOIMMUNE DISEASES; BONE DENSITY; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84860210326     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.10.015     Document Type: Review

References (92)

1. Holick M. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004, 80:1678S-1688S.
2. Economou M., Pappas G. New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis 2008, 14:709-720.
3. Nowson C., Diamond T., Pasco J., Mason R., Sambrook P., Eisman J. Vitamin D in Australia. Aust Fam Physician 2004, 33:133-138.
4. Pappa H., Grand R., Gordon C. Report on the vitamin D status of adult and pediatric patients with inflammatory bowel disease and its significance for bone health and disease. Inflamm Bowel Dis 2006, 12:1162-1174.
5. Peyrin-Biroulet L., Oussalah A., Bigard M. Crohn's disease: the hot hypothesis. Med Hypotheses 2009, 79:94-96.
6. Holick M. Vitamin D deficiency. N Engl J Med 2007, 357(3):266-281.
7. Johnson M., Kimlin M. Vitamin D, aging and the 2005 dietary guidelines for Americans. Nutr Rev 2006, 64:410-421.
8. Alpert P., Shaikh U. The effects of vitamin D deficiency and insufficiency on the endocrine and paracrine systems. Biol Res Nurs 2007, 9:117-129.
9. Albert P., Proal A., Marshall T. Vitamin D: the alternative hypothesis. Autoimmun Rev 2009, 8:639-644.
10. Bouillon R., Carmeliet G., Verlinden L., van Etten E., Verstuyf A., Luderer H.F., et al. Vitamin D and human health: lessons from vitamin D receptor null nice. Endocr Rev 2008, 2008:726-776.
11. Xue Y., Fleet J. Intestinal vitamin D receptor is required for normal calcium and bone metabolism in mice. Gastroenterology 2009, 136:1317-1327.
12. Wada K., Tanaka H., Maeda K., Inoue T., Noda E., Amano R., et al. Vitamin D receptor expression is associated with colon cancer in ulcerative colitis. Oncol Rep 2009, 22:1021-1025.
13. Yu S., Bruce D., Froicu M., Weaver V., Cantorna M.T. Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc Natl Acad Sci U S A 2008, 105:20834-20839.
14. Kong J., Zhang Z., Musch M., Ning G., Sun J., Hart J., et al. Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. Am J Physiol Gastrointest Liver Physiol 2008, 294:G208-G216.
15. Froicu M., Cantorna M. Vitamin D and the vitamin D receptor are critical for control of the innate immune response to colonic injury. BMC Immunol 2007, 8(5).
16. Lim W., Hanauer S., Li Y. Mechanisms of disease: vitamin D and inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2005, 2:308-315.
17. Wang T., Nestel F., Bourdeau V., Nagai Y., Wang Q., Liao J., et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004, 173:2909-2912.
18. Liu P., Stenger S., Li H., et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006, 311:1770-1773.
19. Gombart A., Borregaard N., Koeffler H. Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up-regulated in myeloid cells by 1,25-dihydroxyvitamin D3. FASEB J 2005, 19:1067-1077.
20. Boonstra A., Barratt F., Crain C., Heath V., Savelkoul H., O'Garra A. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001, 167(9):4974-4980.
21. Mahon B.W.A., Wittke A., Weaver V., Cantona M.T. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003, 89(5):922-932.
22. Kamen D., Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med 2010, 88:441-450.
23. Ardizzone S., Cassinotti A., Trabattoni D., Manzionna G., Rainone V., Bevilacqua M., et al. Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int J Immunopathol Pharmacol 2009, 22:63-71.
24. Jeffery L., Burke F., Mura M., Zheng Y., Qureshi O.S., Hewison M., et al. 1,25-Dihydroxyvitamin D3 and IL-2 combine to inhibit T cell production of inflammatory cytokines and promote development of regulatory T cells expressing CTLA-4 and FoxP3. J Immunol 2009, 3:5458-5467.
25. Daniel C., Sartory N., Zahn N., Radeke H.H., Stein J.M. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 2008, 324:23-33.
26. Adorini L., Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008, 4:404-412.
27. Hypponen E., Laara E., Reunanen A., Jarvelin M.R., Virtanen S.M. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001, 358:1500-1503.
28. Munger K., Zhang S., O'Reilly E., Hernan M., Olek M., Willett W., et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004, 62:60-65.
29. Vagianos K., Bector S., McConnell J., Bernstein C.N. Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr 2007, 31(4):311-319.
30. Gaidos J., Sultan S., Dahl W., Valentine J.F. Vitamin D deficiency in inflammatory bowel disease. Digestive Diseases Week (Abstract) 2011.
31. Loftus E. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004, 126:1504-1517.
32. Jantchou P., Clavel-Chapelon F., Carbonnel F., Boutron-Ruault M.C. High sun exposure is associated with a decreased risk of incident Crohn's disease in the E3n cohort study. Digestive Diseases Week (Abstract) 2011.
33. Joseph A., George B., Pulimood A., Seshadri M.S., Chacko A. 25(OH) vitamin D level in Crohn's disease: assocation with sun exposure & disease activity. Indian J Med Res 2009, 130(2):133-137.
34. Chowers Y., Odes S., Bujanover Y., Eliakim R., Bar Meir S., Avidan B. The month of birth is linked to the risk of Crohn's disease in the Israeli population. Am J Gastroenterol 2004, 99:1974-1976.
35. Van Ranst M., Joossens M., Joossens S. Crohn's disease and month of birth. Inflamm Bowel Dis 2005, 11(6):597-599.
36. Sonnenberg A. Occupational distribution of inflammatory bowel disease among German employees. Gut 1990, 31:1037-1040.
37. Ananthakrishnan A., Higuchi L., Khalili H., Bao Y., Korzenik J., Giovannucci E., et al. A prospective study of vitamin D status and risk of incident Crohn's disease and ulcerative colitis. Digestive Diseases Week (Abstract) 2011.
38. Wu S., Xia Y., Liu X., Sun J. Vitamin D receptor deletion leads to reduced level of IkappaBalpha protein through protein translation, protein-protein interaction, and post-translational modification. Int J Biochem Cell Biol 2010, 42:329-336.
39. Jørgensen S., Agnholt J., Glerup H. Clinical trial: vitamin D3 treatment in Crohn's disease - a randomized double-blind placebo-controlled study. Aliment Pharmacol Ther 2010, 32:377-383.
40. Hanley D., Cranney A., Jones G., Whiting S., Leslie W., Cole D., et al. Vitamin D in adult health and disease: a review and guideline statement from Osteoporosis Canada. CMAJ 2010, 182:E610-E618.
41. Jørgensen S., Hvas C., Agnholt J., et al. Vitamin D deficiency in active Crohn's disease. Digestive Diseases Week (Abstract) 2008.
42. Miheller P., Muzes G., Hritz I., Lakatos G., Pregun I., Lakatos P.L., et al. Comparison of the effects of 1,25 Dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients. Inflamm Bowel Dis 2009, 15:1656-1662.
43. Nagpal S., Na S., Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26:662-687.
44. Stio M., Martinesi M., Bruni S. The vitamin D analogue TX 527 blocks NF-kappaB activation in peripheral blood mononuclear cells of patients with Crohn's disease. J Steroid Biochem Mol Biol 2007, 103:51-60.
45. Laverny G., Penna G., Vetrano S., Correale C., Nebuloni M., Danese S., et al. Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. Immunol Lett 2010, 131(1):49-58.
46. Siffledeen J., Fedorak R., Siminoski K., Jen H., Vaudan E., Abraham N., et al. Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. Inflamm Bowel Dis 2004, 10:220-228.
47. Bartram S., Peaston R., Rawlings D., Walshaw D., Francis R., Thompson N. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J Gastroenterol 2006, 12:5680-5686.
48. Gilman J., Shanahan F., Cashman K. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2006, 23:1007-1016.
49. Sylvester F., Wyzga N., Hyams J., Davis P., Lerer T., Vance K., et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:42-50.
50. von Scheven E., Gordon C., Wypij D., Wertz M., Gallagher K., Bachrach L. Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study. J Pediatr Endocrinol Metab 2006, 19:821-830.
51. Paganelli M., Albanese C., Borrelli O., Civitelli F., Canitano N., Viola F., et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:416-423.
52. Sylvester F.A., Wyzga N., Hyams J.S., Davis P.M., Lerer T., Vance K., et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007, 13(1):42-50.
53. Gilman J., Shanahan F., Cashman K.D. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 2006, 23(7):1007-1016.
54. van Hogezand R.A., Hamdy N.A. Skeletal morbidity in inflammatory bowel disease. Scand J Gastroenterol Suppl 2006, 243:59-64.
55. Avernell A., Gillespie W., Gillespie L., O'Connell D. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev 2009, Issue 2(CD000227).
56. Bischoff-Ferrari H., Willett W., Wong J., Giovannucci E, Dietrich T., Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005, 293:2257-2263.
57. Sambrook P., Birmingham J., Kelly P., Kempler S., Nguyen T., Pocock N., et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993, 328:1747-1752.
58. Bernstein C., Seeger L., Anton P., Artinian L., Geffrey S., Goodman W., et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with IBD. Aliment Pharmacol Ther 1996, 10:777-786.
59. Lichtenstein G., Sands B., Pazianas M. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12:797-813.
60. Pohl C., Hombach A., Kruis W. Chronic inflammatory bowel disease and cancer. Hepatogastroenterology 2000, 47:57-70.
61. Garland C., Garland F. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int J Epidemiol 1980, 9:221-231.
62. Hofer H., Ho G., Peterlik M., Uskokovic M., Lee J., White M., et al. Biological effects of 1alpha-hydroxy-and 1beta-(hydroxymethyl)-vitamin D compounds relevant for potential colorectal cancer therapy. J Pharmacol Exp Ther 1999, 291:450-455.
63. Bischof M., Redlich K., Schiller C., Chirayath M., Uskokovic M., Peterlik M., et al. Growth inhibitory effects on human colon adenocarcinoma-derived Caco-2 cells and calcemic potential of 1 alpha,25-dihydroxyvitamin D3 analogs: Structure-function relationships. J Pharmacol Exp Ther 1995, 275:1254-1260.
64. Cross H., Pavelka M., Slavik J., Peterlik M. Growth control of human colon cancer cells by vitamin D and calcium in vitro. J Natl Cancer Inst 1992, 84:1355-1357.
65. Gorham E., Garland C., Garland F., Grant W., Mohr S., Lipkin M., et al. Optimal vitamin D status for colorectal cancer prevention: a quantitative analysis. Am J Prev Med 2007, 32:210-216.
66. Gorham E., Garland C., Garland F., Grant W., Mohr S., Lipkin M., et al. Vitamin D and the prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005, 97:179-194.
67. Wactawski-Wende J., Kotchen J., Anderson G., Assaf A., Brunner R., O'Sullivan M., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354:684-697.
68. Walker E., Gelfand A., Gelfand M., Katon W. Psychiatric diagnoses, sexual and physical victimization, and disability in patients with irritable bowel syndrome or inflammatory bowel disease. Psychol Med 1995, 25:1259-1267.
69. Addolorato G., Capristo E., Stefanini G., Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand J Gastroenterol 1997, 32:1013-1021.
70. Kovacs Z., Kovacs F. Depressive and anxiety symptoms, dysfunctional attitudes, and social aspects in irritable bowel syndrome and inflammatory bowel disease. Int J Psychiatry Med 2007, 37:245-255.
71. Farrokhyar F., Marshall J., Easterbrook B., Irvine E. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm Bowel Dis 2006, 12:38-46.
72. Sullivan M., LaCroix A., Baum C., Grothaus L., Katon W. Functional status in coronary heart disease: a one-year prospective study of the role of anxiety and depression. Am J Med 1997, 103:348-356.
73. Kessler R., Ormel J., Demler O., Stang P. Comorbid mental disorders account for the role impairment of commonly occurring chronic physical disorders: results from the National Comorbidity Survey. J Occup Environ Med 2003, 45:1257-1266.
74. Mardini H., Kip K., Wilson J. Crohn's disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 2004, 49:492-497.
75. Persoons P., Vermeire S., Demyttenaere K., Fischler B., Vandenberghe J., Van Oudenhove L., et al. The impact of major depressive disorder on the short and long-term outcome of Crohn's disease treatment with infliximab. Aliment Pharmacol Ther 2005, 22:101-110.
76. Gartlehner G., Thieda P., Hansen R., Gaynes B., Deveaugh-Geiss A., Krebs E., et al. Comparative risk for harms of second-generation antidepressants: a systematic review and meta-analysis. Drug Saf 2008, 31:851-865.
77. Wilkins C., Sheline Y., Roe C., Birge S., Morris J. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 2006, 14:1032-1040.
78. Armstrong D., Meenagh G., Bickle I., Lee A., Curran E., Finch M. Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clin Rheumatol 2006, 26:551-554.
79. Schneider B., Weber B., Frensch A., Stein J., Fritz J. Vitamin D in schizophrenia, major depression, and alcoholism. J Neural Transm 2000, 107:839-842.
80. Eyles D., Brown J., Mackay-Sim A., McGrath J., Feron F. Vitamin D3 and brain development. Neuroscience 2003, 118:641-653.
81. Garcion E., Wion-Barbot N., Montero-Menei C., Berger F., Wion D. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab 2002, 13:100-105.
82. Zehnder D., Bland R., Williams M., McNinch R., Howie A., Stewart P., et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1-alpha-hydroxylase. J Clin Endocrinol Metab 2001, 86:888-894.
83. Vieth R., Kimball S., Hu A., Walfish P. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100mcg (4000IU) per day on biochemical responses and wellbeing of patients. Nutr J 2004, 3:8.
84. Jorde R., Sneve M., Figenschau Y., Svartberg J., Waterloo K. Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Intern Med 2008, 264:599-609.
85. Harris S., Dawson-Hughes B. Seasonal mood changes in 250 normal women. Psychiatry Res 1993, 49:77-87.
86. Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res 2007, 22:V64-V68.
87. Schwalfenberg G., Genuis S., Hiltz M. Addressing vitamin D deficiency in Canada: a public health innovation whose time has come. Public Health 2010, 124:350-359.
88. Dawson-Hughes B., Heaney R., Holick M., Lips P., Meunier P., Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005, 16:713-716.
89. Narang N., Gupta R., Jain M. Role of vitamin D in pulmonary tuberculosis. J Assoc Physicians India 1984, 32:185-186.
90. Lockefeer J. Vitamin D poisoning; real and spurious. Ned Tijdschr Geneeskd 1990, 134:1931-1934.
91. Vieth R., Bayley T., Walfish P., Rosen I., Pollard A. Relevance of vitamin D metabolite concentrations in supporting the diagnosis of primary hyperparathyroidism. Surgery 1991, 110:1043-1047.
92. Day A., Lemberg D., Messenger R., Woodhead H. High dose vitamin D therapy in paediatric IBD. Digestive Diseases Week (Abstract) 2011.